The safety of live-attenuated vaccines in patients using IL-1 or IL-6 blockade: an international survey

Creative Commons License

Jeyaratnam J., ter Haar N. M., Lachmann H. J., KASAPÇOPUR Ö., Ombrello A. K., Rigante D., ...Daha Fazla

PEDIATRIC RHEUMATOLOGY, cilt.16, 2018 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 16
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1186/s12969-018-0235-z
  • Dergi Adı: PEDIATRIC RHEUMATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Anahtar Kelimeler: Autoinflammatory diseases, Live-attenuated vaccines, Biologicals, IL-1 blockade, IL-6 blockade, JUVENILE IDIOPATHIC ARTHRITIS, AUTOINFLAMMATORY DISEASES, EUROFEVER REGISTRY, RECOMMENDATIONS, VACCINATION, MANAGEMENT, TRIAL
  • Marmara Üniversitesi Adresli: Hayır

Özet

Background: Withholding live-attenuated vaccines in patients using interleukin (IL)-1 or IL-6 blocking agents is recommended by guidelines for both pediatric and adult rheumatic diseases, since there is a risk of infection in an immune suppressed host. However, this has never been studied. This retrospective, multicenter survey aimed to evaluate the safety of live-attenuated vaccines in patients using IL-1 or IL-6 blockade.